{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:39:17Z","timestamp":1787236757515,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00198-019-05103-6","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T05:02:49Z","timestamp":1566622969000},"page":"2391-2400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Bone health in estrogen-free contraception"],"prefix":"10.1007","volume":"30","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-2847","authenticated-orcid":false,"given":"P.-A.","family":"Regidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"issue":"29","key":"5103_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta6290","volume":"6","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd JM (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29):1\u2013146. https:\/\/doi.org\/10.3310\/hta6290","journal-title":"Health Technol Assess"},{"issue":"10","key":"5103_CR2","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/jbmr.2531","volume":"30","author":"JA Kanis","year":"2015","unstructured":"Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30(10):1747\u20131753. https:\/\/doi.org\/10.1002\/jbmr.2531","journal-title":"J Bone Miner Res"},{"key":"5103_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, J\u00f6nsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"issue":"5","key":"5103_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1210\/er.2014-1007","volume":"35","author":"JP Bonjour","year":"2014","unstructured":"Bonjour JP, Chevalley T (2014) Pubertal timing, bone acquisition, and risk of fracture throughout life. Endocr Rev 35(5):820\u2013847. https:\/\/doi.org\/10.1210\/er.2014-1007","journal-title":"Endocr Rev"},{"issue":"11","key":"5103_CR5","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1210\/jc.2012-2561","volume":"97","author":"T Chevalley","year":"2012","unstructured":"Chevalley T, Bonjour JP, van Rietbergen B, Rizzoli R, Ferrari S (2012) Fractures in healthy females followed from childhood to early adulthood are associated with later menarcheal age and with impaired bone microstructure at peak bone mass. J Clin Endocrinol Metab 97(11):4174\u20134181. https:\/\/doi.org\/10.1210\/jc.2012-2561","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"5103_CR6","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1359\/jbmr.1998.13.10.1602","volume":"13","author":"J Cadogan","year":"1998","unstructured":"Cadogan J, Blumsohn A, Barker ME, Eastell R (1998) A longitudinal study of bone gain in pubertal girls: anthropometric and biochemical correlates. J Bone Miner Res 13(10):1602\u20131612. https:\/\/doi.org\/10.1359\/jbmr.1998.13.10.1602","journal-title":"J Bone Miner Res"},{"key":"5103_CR7","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","volume":"359","author":"E Seeman","year":"2002","unstructured":"Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841\u20131850. https:\/\/doi.org\/10.1016\/S0140-6736(02)08706-8","journal-title":"Lancet"},{"issue":"10","key":"5103_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1172\/JCI11468","volume":"106","author":"BL Riggs","year":"2000","unstructured":"Riggs BL (2000) The mechanisms of estrogen regulation of bone resorption. J Clin Investig 106(10):1203\u20131204. https:\/\/doi.org\/10.1172\/JCI11468","journal-title":"J Clin Investig"},{"issue":"2","key":"5103_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/jcem.75.2.1639940","volume":"75","author":"T Lloyd","year":"1992","unstructured":"Lloyd T, Rollings N, Andon MB, Demers LM, Eggli DF, Kieselhorst K, Kulin H, Landis JR, Martel JK, Orr G et al (1992) Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab 75(2):383\u2013387. https:\/\/doi.org\/10.1210\/jcem.75.2.1639940","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"5103_CR10","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/jbmr.95","volume":"25","author":"C Berger","year":"2010","unstructured":"Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC, Hanley DA, CaMos Research Group (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25(9):1948\u20131957. https:\/\/doi.org\/10.1002\/jbmr.95","journal-title":"J Bone Miner Res"},{"issue":"2","key":"5103_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","volume":"166","author":"RL Barbieri","year":"1992","unstructured":"Barbieri RL (1992) Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 166(2):740\u2013745. https:\/\/doi.org\/10.1016\/0002-9378(92)91706-G","journal-title":"Am J Obstet Gynecol"},{"key":"5103_CR12","first-page":"90","volume":"29","author":"M Mawi","year":"2010","unstructured":"Mawi M (2010) Serum estradiol levels and bone mineral density in postmenopausal women. Univ Med 29:90\u201395","journal-title":"Univ Med"},{"issue":"2","key":"5103_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13697130410001713788","volume":"7","author":"A Bagur","year":"2004","unstructured":"Bagur A, Oliveri B, Mautalen C, Belotti M, Mastaglia S, Yankelevich D, Sayegh F, Royer M (2004) Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. Climacteric 7(2):181\u2013188. https:\/\/doi.org\/10.1080\/13697130410001713788","journal-title":"Climacteric"},{"issue":"11","key":"5103_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJM199809103391104","volume":"339","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339(11):733\u2013738. https:\/\/doi.org\/10.1056\/NEJM199809103391104","journal-title":"N Engl J Med"},{"key":"5103_CR15","doi-asserted-by":"publisher","unstructured":"Lopez LM, Grimes DA, Schultz KF, Curtis KM, Chen M. (2014) Steroidal contraceptives: effect on bone fractures in women. Cochrane Database of System Rev (6):CD006033. https:\/\/doi.org\/10.1002\/14651858.CD006033.pub5","DOI":"10.1002\/14651858.CD006033.pub5"},{"issue":"8","key":"5103_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00198-017-4036-X","volume":"28","author":"S Dombrowski","year":"2017","unstructured":"Dombrowski S, Jacob L, Hadji P, Kostev K (2017) Oral contraceptive risk- a retrospective study of 12,970 women in the UK. Osteoporos Int 28(8):2349\u20132355. https:\/\/doi.org\/10.1007\/s00198-017-4036-X","journal-title":"Osteoporos Int"},{"issue":"5","key":"5103_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/01.gco.0000094695.87578.57","volume":"15","author":"BA Cromer","year":"2003","unstructured":"Cromer BA (2003) Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol 15(5):353\u2013357. https:\/\/doi.org\/10.1097\/01.gco.0000094695.87578.57","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"5103_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1530\/EJE-11-1047","volume":"166","author":"D Cibula","year":"2012","unstructured":"Cibula D, Skrenkova J, Hill M, Stepan JJ (2012) Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. Eur J Endocrinol 166(6):1003\u20131011. https:\/\/doi.org\/10.1530\/EJE-11-1047","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"5103_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.bone.2006.08.001","volume":"40","author":"M Hartard","year":"2007","unstructured":"Hartard M, Kleinmond C, Wiseman M (2007) Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone. 40(2):444\u2013450. https:\/\/doi.org\/10.1016\/j.bone.2006.08.001","journal-title":"Bone."},{"issue":"12","key":"5103_CR20","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1007\/s00198-005-1868-6","volume":"16","author":"SH Almstedt","year":"2005","unstructured":"Almstedt SH, Snow CM (2005) Oral contraceptive use in young women is associated with lower bone mineral density than that of controls. Osteoporos Int 16(12):1538\u20131544. https:\/\/doi.org\/10.1007\/s00198-005-1868-6","journal-title":"Osteoporos Int"},{"issue":"5","key":"5103_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2265.2009.03688.x","volume":"72","author":"M Herrmann","year":"2010","unstructured":"Herrmann M, Seibel MJ (2010) The effects of hormonal contraceptives on bone turnover markers and bone health. Clin Endocrinol 72(5):571\u2013583. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03688.x","journal-title":"Clin Endocrinol"},{"issue":"4","key":"5103_CR22","first-page":"401","volume":"107","author":"PD Broul\u00edk","year":"2006","unstructured":"Broul\u00edk PD, Broul\u00edkov\u00e1 K, Ne\u010das E (2006) Progestogens androgenic action on the bone of male castrated mice. Prague Medical Report 107(4):401\u2013408","journal-title":"Prague Medical Report"},{"issue":"4","key":"5103_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1081\/ERC-100107870","volume":"27","author":"OA Onobrakpeya","year":"2001","unstructured":"Onobrakpeya OA, Fall PM, Willard A, Chakravarthi P, Hansen A, Raisz LG (2001) Effect of norethindrone acetate on hormone levels and markers of bone turnover in estrogen-treated postmenopausal women. Endocr Res 27(4):473\u2013480","journal-title":"Endocr Res"},{"issue":"4","key":"5103_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ajog.2004.12.067","volume":"192","author":"JH Liu","year":"2005","unstructured":"Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192(4):1316\u20131323; discussion 1323\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2004.12.067","journal-title":"Am J Obstet Gynecol"},{"issue":"12 Sup","key":"5103_CR25","first-page":"1007","volume":"38","author":"A DeCherney","year":"1993","unstructured":"DeCherney A (1993) Physiologic and pharmacologic effects of estrogen and progestins on bone. J Reprod Med 38(12 Sup):1007\u20131014 Review","journal-title":"J Reprod Med"},{"issue":"5","key":"5103_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.contraception.2006.06.005","volume":"74","author":"M Hartard","year":"2006","unstructured":"Hartard M, Kleinmond C, Luppa P (2006) Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13\u00a0cycles. Contraception. 74(5):365\u2013375. https:\/\/doi.org\/10.1016\/j.contraception.2006.06.005","journal-title":"Contraception."},{"issue":"2","key":"5103_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jogc.2015.12.002","volume":"38","author":"A Black","year":"2016","unstructured":"Black A, Guilbert Q, Costescu D, Dunn S, Fisher W, Kives S, Mirosh M, Norman W, Pymar H, Reid R, Roy G, Varto H, Waddington A, Wagner MS, Whelan AM, Mansouri S (2016) Canadian contraception Consensus (Part 3 of 4): Chapter 7 \u2013 Intrauterine contraception. J Obstet Gynaecol Can 38(2):182\u2013222. https:\/\/doi.org\/10.1016\/j.jogc.2015.12.002","journal-title":"J Obstet Gynaecol Can"},{"key":"5103_CR28","doi-asserted-by":"publisher","unstructured":"Mansour D (2012) The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception. https:\/\/doi.org\/10.1016\/j.contraception.2011.08.003","DOI":"10.1016\/j.contraception.2011.08.003"},{"issue":"2","key":"5103_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jbspin.2008.09.014","volume":"76","author":"J Sarfati","year":"2009","unstructured":"Sarfati J, Marie-Christine De Vernejoul MC (2009) Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine 76(2):134\u2013138. https:\/\/doi.org\/10.1016\/j.jbspin.2008.09.014","journal-title":"Joint Bone Spine"},{"issue":"6","key":"5103_CR30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00404-015-3784-0","volume":"292","author":"W Modesto","year":"2015","unstructured":"Modesto W, Dal Ava N, Monteiro I, Bahamondes L (2015) Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet 292(6):1387\u20131391. https:\/\/doi.org\/10.1007\/s00404-015-3784-0","journal-title":"Arch Gynecol Obstet"},{"issue":"5 - part 19","key":"5103_CR31","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0029-7844(00)00782-1","volume":"96","author":"DB Petitti","year":"2000","unstructured":"Petitti DB, Piagio G, Metha S, Cravioto MC, Meirik O (2000) Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 96(5 - part 19):736\u2013744. https:\/\/doi.org\/10.1016\/S0029-7844(00)00782-1","journal-title":"Obstet Gynecol"},{"issue":"1","key":"5103_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/humrep\/15.1.118","volume":"15","author":"R Beerthuizen","year":"2000","unstructured":"Beerthuizen R, van Beek A, Massai R, M\u00e4k\u00e4r\u00e4inen L, In\u2019t Hout J, Bennink HC (2000) Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15(1):118\u2013122. https:\/\/doi.org\/10.1093\/humrep\/15.1.118","journal-title":"Hum Reprod"},{"issue":"6793","key":"5103_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.303.6793.13","volume":"303","author":"T Cundy","year":"1991","unstructured":"Cundy T, Evans M, Roberts H (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 303(6793):13\u201316. https:\/\/doi.org\/10.1136\/bmj.303.6793.13","journal-title":"BMJ."},{"issue":"1","key":"5103_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/jc.2002-020874","volume":"88","author":"T Cundy","year":"2003","unstructured":"Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G et al (2003) A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 88(1):78\u201381. https:\/\/doi.org\/10.1210\/jc.2002-020874","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5103_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1210\/jc.2007-2201","volume":"93","author":"JS Walsh","year":"2008","unstructured":"Walsh JS, Eastell R, Peel NF (2008) Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab 93(4):1317\u20131323. https:\/\/doi.org\/10.1210\/jc.2007-2201","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5103_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1210\/jcem.86.1.7118","volume":"86","author":"SM Ott","year":"2001","unstructured":"Ott SM, Scholes D, Lacroix AZ, Ichikawa LE, Yoshida CK, Barlow WE (2001) Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab 86(1):179\u2013185. https:\/\/doi.org\/10.1210\/jcem.86.1.7118","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5103_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00198-016-3714-4","volume":"28","author":"I Kyvernitakis","year":"2017","unstructured":"Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P (2017) The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int 28(1):291\u2013297. https:\/\/doi.org\/10.1007\/s00198-016-3714-4","journal-title":"Osteoporos Int"},{"issue":"6","key":"5103_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.contraception.2006.01.006","volume":"73","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Oral contraceptive use and risk of fracture. Contraception 73(6):571\u2013576. https:\/\/doi.org\/10.1016\/j.contraception.2006.01.006","journal-title":"Contraception"},{"issue":"11","key":"5103_CR39","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1210\/jc.2010-0032","volume":"95","author":"C Meier","year":"2010","unstructured":"Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR (2010) Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 95(11):4909\u20134916. https:\/\/doi.org\/10.1210\/jc.2010-0032","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"5103_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0022-3476(96)70148-8","volume":"129","author":"BA Cromer","year":"1996","unstructured":"Cromer BA, Blair JM, Mahan JD et al (1996) A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 129(5):671\u2013676. https:\/\/doi.org\/10.1016\/S0022-3476(96)70148-8","journal-title":"J Pediatr"},{"issue":"3","key":"5103_CR41","first-page":"431","volume":"96","author":"L Miller","year":"2000","unstructured":"Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, David A, Eschenbach DA (2000) Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 96(3):431\u2013439","journal-title":"Obstet Gynecol"},{"key":"5103_CR42","unstructured":"ORTHO-McNEIL (1998) Ortho Micronor\u00ae tablets (noretindrone) Pharmaceutical, INC. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/016954s101lbl.pdf."},{"issue":"6","key":"5103_CR43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2265.1994.tb02788.x","volume":"41","author":"LE Caird","year":"1994","unstructured":"Caird LE, Reid-Thomas V, Hannan WJ et al (1994) Oral progestogen-only contraception may protect against loss of bone mass in breastfeeding women. Clin Endocrinol 41(6):739\u2013745. https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02788.x","journal-title":"Clin Endocrinol"},{"issue":"Sup1","key":"5103_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/09513590701584931","volume":"23","author":"JH Thijssen","year":"2007","unstructured":"Thijssen JH (2007) Long-term effects of progestins on bone quality and fractures. Gynecol Endocrinol 23(Sup1):45\u201352. https:\/\/doi.org\/10.1080\/09513590701584931","journal-title":"Gynecol Endocrinol"},{"key":"5103_CR45","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/humrep\/dep469","volume":"25","author":"T Strowitzki","year":"2010","unstructured":"Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633\u2013641. https:\/\/doi.org\/10.1093\/humrep\/dep469","journal-title":"Hum Reprod"},{"issue":"11","key":"5103_CR46","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1177\/0091270011423664","volume":"52","author":"C Klipping","year":"2012","unstructured":"Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B (2012) Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 52(11):1704\u20131713. https:\/\/doi.org\/10.1177\/0091270011423664","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"5103_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1447-0756.2009.01076.x","volume":"35","author":"M Momoeda","year":"2009","unstructured":"Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H, Taketani Y (2009) Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 35(6):1069\u20131076. https:\/\/doi.org\/10.1111\/j.1447-0756.2009.01076.x","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"5103_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/humrep\/14.4.982","volume":"14","author":"CF Rice","year":"1999","unstructured":"Rice CF, Killick SR, Dieben T, Bennink HC (1999) A comparison of the inhibition of ovulation achieved by desogestrel 75\u00a0mg and levonorgestrel 30\u00a0mg daily. Hum Reprod 14(4):982\u2013985. https:\/\/doi.org\/10.1093\/humrep\/14.4.982","journal-title":"Hum Reprod"},{"issue":"4","key":"5103_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","volume":"54","author":"U Fuhrmann","year":"1996","unstructured":"Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH (1996) The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 54(4):243\u2013251. https:\/\/doi.org\/10.1016\/S0010-7824(96)00195-3","journal-title":"Contraception."},{"issue":"6","key":"5103_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/13625187.2015.1044082","volume":"20","author":"IJM Duijkers","year":"2015","unstructured":"Duijkers IJM, Herger-Mahn D, Drouin D, Skouby S (2015) A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24\/4 regimen. Eur J Contracept Reprod Health Care 20(6):419\u2013427. https:\/\/doi.org\/10.3109\/13625187.2015.1044082","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"5103_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/oxfordjournals.humrep.a019245","volume":"11","author":"C Rice","year":"1996","unstructured":"Rice C, Killick S, Hickling D, Bennink HC (1996) Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 11(4):737\u2013740. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a019245","journal-title":"Hum Reprod"},{"issue":"11","key":"5103_CR52","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1359\/jbmr.2001.16.11.2118","volume":"16","author":"PM Doran","year":"2001","unstructured":"Doran PM, Riggs BL, Atkinson EJ, Khosla S (2001) Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16(11):2118\u20132125. https:\/\/doi.org\/10.1359\/jbmr.2001.16.11.2118","journal-title":"J Bone Miner Res"},{"key":"5103_CR53","unstructured":"Slynd \u00ae: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211367s000lbl.pdf"}],"updated-by":[{"DOI":"10.1007\/s00198-020-05426-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-019-05103-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T10:03:00Z","timestamp":1645783380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-019-05103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5103"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05103-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"11 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-020-05426-9","URL":"https:\/\/doi.org\/10.1007\/s00198-020-05426-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Peyman Hadji had received traveling support and speaker\u2019s fees from Amgen, Dr. Kade\/Besin, Elly Lilly, Exeltis, Gedeon Richter, MEDA, MSD, Mylan, Theramex, and UCB: Enrico Colli and Pedro-Antonio Regidor are employees of Exeltis Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}